Some cetaceans bioaccumulate substantial concentrations of planar halogenated aromatic hydrocarbons (PHAHs) in their tissues, but little is known about the effects of such burdens on cetacean health. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and related PHAHs cause toxicity via activation of the aryl hydrocarbon receptor (AHR), a member of the bHLH-PAS family of transcription factors. Differences in AHR structure and function are known to contribute to species-specific differences in susceptibility to PHAH toxicity. To ascertain the potential for PHAH effects in a cetacean, we characterized an AHR from the beluga whale, Delphinapterus leucas. Together, these results demonstrate that the use of in vitro-expressed proteins is a promising approach for addressing molecular and biochemical questions concerning PHAH toxicity in endangered or protected species.
Persistent organic pollutants (POPs) are ubiquitous in the marine environment. These compounds are generally hydrophobic and resistant to metabolic and chemical degradation, and thus tend to partition to lipid-rich components of tissues and cellular compartments. Because many POPs tend to bioaccumulate, organisms at the highest trophic levels-including marine mammals such as odontocete cetaceans (toothed whales)-may be exposed to high concentrations of these compounds. For example, beluga whales (Delphinapterus leucas, family Delphinidae) that inhabit the St. Lawrence Estuary, Canada, accumulate polychlorinated biphenyl (PCB) concentrations as high as 500 g/g wet weight in blubber (Martineau et al., 1987; Muir et al., 1990 Muir et al., , 1996 . Consequently, POP exposure has long been suspected of playing a role in the observed cancer and reduced rate of reproduction in this population (Beland et al., 1993; De Guise et al., 1995; Martineau et al., 1994) . However, evaluation of the actual effects of POPs in beluga and other cetacean species and populations is hindered by the possible interplay of multiple environmental variables, including habitat degradation and the occurrence of high levels of other types of anthropogenic pollutants. Furthermore, establishing definitive cause and effect relationships is difficult, because logistical, moral, or ethical concerns preclude direct toxicity testing in cetaceans.
Among the several classes of POPs, the planar halogenated aromatic hydrocarbons (PHAH) are known to be especially toxic to vertebrate animals. PHAHs include 2, 3, 7, , other polychlorinated dibenzo-pdioxins, polychlorinated dibenzofurans, and certain non-and mono-ortho-substituted PCBs. These compounds cause a number of toxic and biochemical effects in laboratory rodents, including immunosuppression, endocrine dysfunction, enzyme induction, cancer, and reproductive/developmental toxicity (Pohjanvirta and Tuomisto, 1994; Poland and Knutson, 1982; Schmidt and Bradfield, 1996) . Although the mechanisms by which TCDD and other PHAHs cause toxicity are not completely understood, it is known that these compounds exert their toxic and gene-regulatory effects via the aryl hydrocarbon receptor (AHR) (Hahn, 1998a; Poland et al., 1976; Schmidt and Bradfield, 1996) , a soluble, ligand-activated transcription factor and a member of the basic helix-loop-helix family of transcription factors (Gu et al., 2000) . Studies in AHR-null mice have shown that this protein is required for TCDD toxicity (Fernandez-Salguero et al., 1996; Hundeiker et al., 1999; Mimura et al., 1997; Peters et al., 1999; Thurmond et al., 2000) . In addition, strain-and species-specific differences in sensitivity to the effects of TCDD have been shown to depend, at least in part, on the properties of the respective AHRs, including their ligand-binding affinities (Ema et al., 1994b; Poland et al., 1994; Sanderson and Bellward, 1995) .
Several laboratories have provided evidence for a functional AHR signal transduction pathway in cetaceans. Cytochrome P450 (CYP) forms in the 1A and 1B subfamilies, which in other mammals are regulated by the AHR, have been identified by catalytic, immunochemical, and molecular assays in cetaceans (Godard et al., 2000; Goksøyr et al., 1986 Goksøyr et al., , 1988 Teramitsu et al., 2000; White et al., 1994) . A strong correlation between hepatic levels of CYP1A1 and blubber concentrations of non-ortho-substituted PCBs provided indirect evidence for CYP1A1 induction in beluga from the Arctic (White et al., 1994) . The presence of a cetacean AHR that is capable of specific binding to dioxins was confirmed using dolphin kidney cell lysates (Carvan et al., 1994) and beluga liver cytosol .
To assess the potential susceptibility of cetaceans to PHAHs, we are characterizing the AHR signaling pathway of the beluga Jensen, 2000; White et al., 1994 White et al., , 2000 . This species was chosen for several reasons: (1) the existence of distinct stocks that vary in their exposure to PHAHs (Muir et al., 1990) ; (2) the postulated role of PHAH in the decline of the St. Lawrence beluga stock (De Guise et al., 1995; Martineau et al., 1994; Sargeant and Hoek, 1988) ; (3) the recent proposal of beluga as a "model odontocete cetacean species" by a working group of marine mammal toxicologists convened by the Marine Mammal Commission (Marine Mammal Commission, 1999) ; and (4) the potential for follow-up research on captive populations. In the present report, we describe the cloning, in vitro expression, and initial functional analysis of a beluga AHR. We compare this beluga AHR to a relatively high affinity AHR, the product of the mouse Ah b-1 allele (Burbach et al., 1992; Ema et al., 1992; Poland et al., 1994) , as well as to the human AHR (Dolwick et al., 1993a) . This is the first molecular characterization of an AHR in a marine mammal. The results of these analyses suggest that beluga may be sensitive to the effects of PHAHs. More generally, our results show that cDNA cloning with in vitro characterization of proteins involved in mechanisms of toxicity is a promising approach for gathering species-specific data that may contribute to an improved understanding of the contaminant sensitivity of protected species, for which in vivo dosing experiments are ethically, legally, and logistically impossible.
MATERIALS AND METHODS

Materials. Expression vectors for the mouse AHR (pSPORTmoAHR;
Ah b-1 allele; Burbach et al., 1992) , human AHR (pSPORThuAHR2; Dolwick et al., 1993a) , and human Arnt (pSPORTArnt) were graciously provided by Dr. C. Bradfield (McArdle Center for Cancer Research, Madison WI). The luciferase reporter construct pGudLuc6.1, derived from pGudLuc1.1 (Garrison et al., 1996) as described elsewhere (Long et al., 1998) , was a gift from Dr. M. Denison (U.C. Davis). 2, 3, 7, H]dibenzo-p-dioxin (33 Ci/ mmol) was obtained from Chemsyn Science Laboratories (Lenexa, KS) and purified to ϳ95% radiochemical purity by high performance liquid chromatography (Gasiewicz and Neal, 1979 (DottavioMartin and Ravel, 1978) . Charcoal (Norit A alkaline) was from Fisher Scientific. The C57BL/6 mouse was provided by Dr. D. S. Sherr (Boston University School of Public Health, Boston, MA).
Tissue collection. Beluga liver was collected from Mackenzie River Delta, NWT, Canada, as described earlier (White et al., 1994) . Liver tissue was also collected from a subsistence hunt of Chukchi Sea beluga in Alaska during the summer of 1997. Liver tissue was snap frozen in liquid nitrogen approximately 3-4 hours after death. Tissues were maintained at liquid nitrogen temperatures throughout transport, storage, and powdering with mortar and pestle. The C57BL/6J mouse was killed by cervical dislocation and the liver was extracted from the animal and snap frozen minutes after death.
RNA isolation. Total RNA was isolated from liver tissue using the guanidinium isothiocyanate method (Clemens, 1984) . PolyA ϩ RNA was isolated using oligo dT columns (Collaborative Research, Bedford MA) as described by Maniatis et al. (1982) . The quality of the total and polyA ϩ RNA was confirmed by visualization on ethidium bromide-stained agarose minigels and quantity was determined by UV absorbance.
Oligonucleotide primers. Primers were synthesized by National Biosciences, Life Technologies, or Integrated DNA Technologies. The degenerate primers AHR-A1, AHR-A2, AHR-B1, and AHR-B2 have been described previously (Hahn and Karchner, 1995; Karchner and Hahn, 1996) . The genespecific primers used are presented in Table 1 . Dlb538  5Ј-TTC CTT TGG CAT CAC AAC CAG TAG-3Ј  Dlb467  5Ј-CGG ATT TCA AGT ATG GAT GGT GG-3Ј  Dlf152  5Ј-GGG CGT TAA ATC CTT CAC AGT GTC C-3Ј  Dlf258  5Ј-GAA CTC TTC GTC TAT GGA AAG GTG C-3Ј  Dlf467  5Ј-CCA CCA TCC ATA CTT GAA ATC CG-3Ј  Dlf538  5Ј-CCT ACT GGT TGT GAT GCC AAA GGA A-3Ј  DlExon9F 5Ј-TGC AGT CGA ATG CAC GCT TAG-3Ј DlUTRrev 5Ј-AAC CAA GAT GAA AAA TGG GCT TG-3Ј 5nat-hind3 5Ј-CCC AAG CTT GGG CAC CAT GAA CAG CAG C-3Ј 5koz-hind3 5Ј-CCC AAG CTT GGG CAC CAT GGA CAG CAG C-3Ј xba1-utr 5Ј-GCT CTA GAG CAA CCA AGA TGA AAA ATG GGC TTG-3Ј
Cloning and sequencing of beluga AHR cDNA. PolyA ϩ RNA isolated from a beluga that stranded in the Mackenzie River Delta, Canada, was used for synthesis of cDNA using random hexamers. Degenerate primers AHR-A2 and AHR-B2 containing inosines were used to amplify an internal beluga AHR fragment from the cDNA with the following PCR conditions: 94°C/5:00 min (95°/0:15 s, 45°/0:30, 72°/1:00) for 45 cycles, followed by a 7-min final extension (72°C). The same primers were used in direct sequencing of the amplified fragment in both directions using the Sequenase Version 2 Kit (U.S. Biochemical) with modifications for direct sequencing as described by Bachmann et al. (1990) . Sequencing revealed 480 base pairs (bp) that shared high sequence identity with mammalian AHRs. Subsequent efforts to obtain a full-length clone using Rapid Amplification of cDNA Ends (RACE) (Frohman et al., 1988; Ohara et al., 1989) were unsuccessful. Suspecting that sample quality may have been compromised, we turned our efforts to beluga samples obtained in 1997 from Alaska.
PolyA ϩ mRNA isolated from the Alaskan beluga was used with a GeneAmp RT/PCR kit (Applied Biosystems), with the following conditions in the Perkin Elmer 2400 thermocycler: 94°/5:00 (95°/0:15, 60°/0:30, 72°/1:00) for 35 cycles. Degenerate primers AHR-A1 and AHR-B1 containing inosines amplified a 648-bp fragment that was sequenced with a Licor4000 automated sequencing system using an Excel II cycle sequencing kit (Epicentre Technology). Gene-specific primers were then designed for 5Ј-and 3Ј-RACE. The 5Ј gene-specific primers Dlb538 and Dlb467 and the 3Ј gene-specific primers Dlf152, Dlf258, Dlf467, and Dlf538 were used with the Marathon gene amplification kit (Clontech). To maximize specificity, "touchdown" PCR (Don et al., 1991) was used for all RACE reactions: 94°/0:30 min (94°/0:05, 72°/2:00) (5 cycles); (94°/0:05,70°/2:00) (5 cycles); and (94°/0:05, 68°/2:00) (25 cycles). Nested 5Ј-RACE was carried out on the Dlb538 product using Dlb467. The 3Ј-RACE products were too large to sequence outright, so an additional PCR was performed to obtain the remaining sequence of the 3Ј-RACE clone using DLExon9F and DlUTR1rev with conditions 95°/5:00 (95°/0:30,56°/0:30,72°/0:30) (35 cycles); 72°/7:00. All sequencing was carried out on the Licor4000 automated sequencing system using an Excel II cycle sequencing kit. RT-PCR and RACE products were assembled to determine the consensus beluga AHR sequence. This sequence was based on 44 individual fragments; 38 were obtained by cycle sequencing of 21 separate clones and 6 sequences were from direct sequencing of PCR products in forward and reverse directions. The minimum number of sequences that were used to form a consensus at each base was 4 within the coding region and 2 in the untranslated regions (UTRs).
Multiple alignment of beluga, mouse, and human AHR was done with the ClustalW program contained in the MacVector software, version 6.5.3 (Oxford Molecular).
Expression vector construction.
Once sequencing revealed the start and stop codons, primers were designed to amplify the full-length cDNA. Two 5Ј primers were designed, one with the native sequence (5nat-hind3) and the other with a Kozak sequence (5koz-hind3) (A3 G switch at ϩ4) (Kozak, 1987) . Both contained HindIII restriction sites outside of the coding region. The full-length beluga AHR was amplified using Klentaq DNA polymerase (Clontech). Primer pairs 5nat-hind3/xba1-utr and 5koz-hind3-/xba1-utr were used in touchdown PCR: 94°/1:00 (94°/0:05, 70°/2:00) (5 cycles); (94°/0:05, 68°/2:00) (5 cycles); (94°/0:05, 66°/2:00) (25 cycles); and 68°/7:00.
The full-length AHR products derived from primer pairs 5nat-hind3/xba1-utr and 5koz-hind3-/xba1-utr were cloned into the HindIII and XbaI sites of pcDNA3.0 (Invitrogen) and pSP64 Poly(A) (Promega) vectors. This generated constructs containing native and Kozak 5Ј ends, each under control of either the T7 or SP6 promoter. The 4 constructs were tested for expression efficiency. Proteins were synthesized using the TNT Quick Coupled Transcription and Translation system (Promega) for T7 or SP6 promoters in the presence of [
35 S]-methionine. The pSP64belAHRnat construct under control of the SP6 promoter expressed 2-to 3-fold higher levels of protein compared to the pcDNA constructs. The pcDNAbelAHRkoz construct expressed at higher levels compared with the pcDNAbelAHRnat sequence. Thus, the pSP64belAHRnat was used for in vitro translation studies, and the pcDNAbelAHRkoz was used for transfection experiments. To ensure that the pSP64belAHRnat expression plasmid (hereafter referred to as pSP64belAHR) and the pcDNAbelAHRkoz (hereafter referred to as pcDNAbelAHR) were free of PCR errors, each was completely sequenced and confirmed to match the belAHR consensus sequence that had been determined by RT-PCR and RACE.
Cytosol preparation. Liver cytosol was prepared as described in . Cryo-preserved liver was first powdered while under liquid nitrogen, then homogenized in MEEDGM (25 mM MOPS, 1 mM EDTA, 5 mM EGTA, 0.02% NaN 3 , 20 mM Na 2 MoO 4 , 10% (v:v) glycerol, 1 mM DTT, pH 7.5) containing protease inhibitors (100 u/ml aprotinin, 7 g/ml pepstatin A, 5 g/ml leupeptin, 20 M tosyl-L-phenylalanine chloromethyl ketone, and 0.1 mM phenylmethylsulfonyl fluoride). After serial centrifugations of 750g, 12,000g, and 100,000g, the supernatants were frozen in liquid nitrogen until analysis.
In vitro protein synthesis. Beluga, mouse and human AHR proteins were synthesized using the TNT Quick coupled Reticulocyte Lysate Systems (Promega) in the presence or absence of [
35 S]-labeled methionine. The sizes of the proteins were confirmed by SDS-PAGE with 2 l of a 25-l TNT reaction containing [
35 S]-labeled AHR (approximately 25 g total protein), followed by fluorography and autoradiography.
Western blotting. Two l of in vitro (TNT) synthesized mouse, human, and beluga AHRs and 100 g beluga liver cytosolic protein were loaded onto a Tris-acetate gel (Novex). The gel was blotted onto 0.22 m PVDF membrane, and probed with SA-210 rabbit antimouse AHR polyclonal antibody (Biomol) and secondary goat antirabbit antibody (Schleicher & Schuell). Bands were visualized with CSPD chemiluminescent substrate (Tropix).
Velocity sedimentation.
In vitro-expressed beluga, mouse, and human AHR were analyzed by velocity sedimentation on sucrose gradients in a vertical tube rotor (Tsui and Okey, 1981) . For each AHR or unprogrammed lysate control, two identical TNT reactions (100 l total) were combined and diluted 1:2 with MEEDMG buffer (described above). Each sample was split into 2 aliquots and incubated with [ 3 H]TCDD (2 nM) Ϯ TCDF (400 nM) for 8 h at 4°C in glass tubes. Following incubation, the expressed proteins were treated with 1.5 mg/ml dextran-coated charcoal (DCC) (charcoal:dextran 10:1 w:w) in a polypropylene tube. Cytosols were diluted to 5 mg protein/ml in MEEDMG buffer and incubated under the same conditions as the expressed proteins except that they were not washed with DCC. The [ 3 H]TCDD concentration was verified by sampling each tube for total counts. Samples were analyzed on 10 -30% sucrose gradients as described earlier Poland et al. (1976) . The beluga, mouse, and human AHR proteins were synthesized by in vitro transcription and translation as for the velocity sedimentation assay. The reactions were then diluted 1:8 in MEEDGM with protease inhibitors. Diluted TNT-expressed proteins were incubated in 16 ϫ 100-mm glass tubes for 7-8 h with each of 9 concentrations (0 to 8 nM nominal) of [ 3 H]TCDD in DMSO. Duplicate aliquots were taken at the beginning of the incubation to measure the actual concentrations of [ 3 H]TCDD in each tube. After the incubation, 30 l were transferred in triplicate aliquots to standard, 1.5-ml polypropylene tubes containing 30 l of 2.3 mg DCC/ml MEEDGM. Tubes were vortexed ϫ 3 for 5 s, with a 5-min incubation on ice between each vortexing. After a short spin to sediment the DCC, 40 l of the supernatant were counted to measure bound [ 3 H]TCDD. Total counts and total binding were measured on a Beckman 5000 scintillation counter.
A difference in the assay used here as compared to the original method (Poland et al., 1976 ) is our use of "unprogrammed" TNT lysate (UPL; TNT lysate plus an empty expression vector) to determine nonspecific binding. In tissue-based AHR binding assays, specific binding is determined from the difference between total [
3 H]TCDD binding and the [ 3 H]TCDD binding measured when excess cold ligand (usually TCDF) is used to block specific binding sites. The use of in vitro-expressed proteins provides the opportunity to measure nonspecific binding directly, by using a blank reaction containing UPL. Sucrose gradient analysis showed that UPL lacks specific binding when assayed in the presence and absence of excess TCDF (see Results and Karchner et al., 1999) . Therefore, analysis of unprogrammed TNT lysate provides a convenient means for measuring nonspecific binding without the need for duplicate tubes for each species tested. This method also avoids potential artifacts associated with the use of high concentrations of TCDF, which is poorly soluble in aqueous solutions.
All curves were plotted as "free" 
where B is specifically bound [ 3 H]TCDD, B max is maximum bound receptor, L is the concentration of free ligand, and K d is the equilibrium dissociation constant. Nonlinear regression analysis is the method of choice for determination of K d and B max , because it avoids the statistical disadvantages of linear transformations such as the traditional Scatchard analysis (Kenakin, 1999) . The K d values from 4 experiments each for beluga, mouse, and human AHRs were compared using one way ANOVA and Tukey's multiple-comparisons test. Curve fits were done with SigmaPlot 5.0 for the Macintosh (Jandel Scientific) and statistics were done with Prism version 3 software for the Macintosh (GraphPad).
Electrophoretic mobility shift assays. Electrophoretic mobility shift assays were performed using wild type and mutant DRE-containing oligonucleotides (Yao and Denison, 1992) . Oligonucleotides were: wild-type (5Ј-GAT CTG GCT CTT CTC ACG CAA CTC CG-3Ј and 5Ј-CGG AGT TGC GTG AGA AGA GCC AGA TC-3Ј ) and mutant (5Ј-GAT CTG GCT CTT CTC ACA CAA CTC CGG ATC-3Ј and 5Ј-GAT CCG GAG TTG TGT GAG AAG AGC CAG ATC-3Ј) (core sequence in bold; mutations underlined). To generate labeled dioxin-responsive enhancer (DRE)-containing probes, one strand of the wild-type DRE oligonucleotide was radiolabeled with [␥ 32 P]-ATP using T4 kinase according to the manufacturer's recommendations (Promega). After the labeling reaction, the complementary strand was added and annealed to the labeled strand by heating the combined oligonucleotides to 90°C and allowing them to slowly cool to room temperature. Unincorporated radionucleotides were removed by spinning the product through a Centri-Spin 20 column (Princeton Separations). For competition experiments, a double-stranded, unlabeled wild-type DRE oligonucleotide and a mutant DRE oligonucleotide that contains a single base pair substitution within the DRE core consensus sequence were used.
Prior to initiation of the in vitro expression reaction, the TNT Master Mix (Promega) was incubated with 2.5 g DCC per l Master Mix for 10 min on ice Powell et al., 1999) . The DCC was then pelleted, and the Master Mix was removed and used in the in vitro expression reactions with pSP64belAHR, pSPORTmoAHR, and pSPORTArnt. Three l of either the beluga or mouse AHR reactions were mixed with 3 l human Arnt reaction and MEEDG (10 mM MOPS buffer, pH 7.5 with 1 mM dithiothreitol, 1 mM EDTA, 5 mM EGTA, 0.02% NaN3, and 10% glycerol). Where AHR or Arnt was left out of the reaction, an equal volume of unprogrammed lysate was substituted. Acetone or 40 nM TCDD was then added, and the mixture incubated for 2 h. For the competition assays, 3 l unlabeled DRE, 3 l mutant DRE, 0.6 g anti-moAHR antibody (Biomol), or 0.6 g rabbit IgG was added for an additional 15-min incubation. Finally, a master mix containing NaCl (165 mM final), pdIdC (1.25 g/l), glycerol (10%), and labeled DRE probe (50,000 cpm/rxn) was added to all tubes, and the incubation was continued for an additional 30 min. All incubations were at room temperature. The samples were resolved on a 4.5% TBE gel, and the gel was dried and exposed to X-ray film overnight.
Transfection assays. COS-7 monkey kidney cells, which express no AHR and very little Arnt (Ema et al., 1994a,b) were transfected with human Arnt and beluga or mouse AHR, together with pGudLuc6.1 and a renilla luciferase plasmid (pRL-TK, Promega), to serve as the transfection control. pGudLuc6.1 contains the firefly luciferase gene under control of an MMTV promoter regulated by 4 DREs within a 480-bp fragment derived from the murine Cyp1A1 promoter (Long et al., 1998) . Cells were transfected with 0, 10, or 50 ng of pcDNAbelAHR or pSPORTmoAHR, 0 or 50 ng pSPORTArnt, 20 ng GudLuc6.1, and 3 ng pRL-TK. The empty vector pcDNA3.1 (100 -290 ng) was used to bring the total amount of DNA transfected to approximately 300 ng.
The transfection protocol was as follows. First, COS-7 cells were plated at 40,000 cells/well of a 48-well plate. Twenty-four hours later, the medium was replaced with serum-free medium and the cells were transfected using the Lipofectamine 2000 reagent (Gibco) as described by the manufacturer. Five hours later, cells were dosed with DMSO or 10 nM TCDD. Eighteen hours after dosing, the cells were harvested and luciferase activity was measured using the Dual Luciferase Reporter Assay System (Promega) on a Turner TD-20/20 luminometer (Turner Designs).
RESULTS
Beluga AHR cloning.
A beluga AHR cDNA was isolated from liver of beluga whales collected from Canada and Alaska. The initial sequencing utilized liver tissue from a beluga that was stranded in the Mackenzie River Delta, Canada. This individual was among those from which PCB levels and CYP1A expression were measured (White et al., 1994) and an AHR was identified by photo-affinity labeling . Using degenerate primers, whose design was based on previously published mammalian AHR sequences (Hahn and Karchner, 1995; Karchner and Hahn, 1996) , we isolated the AHR-A2/AHR-B2 fragment after using low-stringency conditions. Efforts to isolate the full-length beluga AHR cDNA using the Mackenzie River Delta beluga sample were not successful, so subsequent efforts utilized a beluga liver sample collected in Alaska in 1997. From freshly prepared mRNA, a 648-bp AHR-A1/AHR-B1 fragment was isolated that encompassed the AHR-A2/AHR-B2 fragment and matched its sequence exactly. The remaining beluga AHR sequence was obtained with 5Ј-and 3Ј-RACE using the 1997 Alaskan sample. Together, the RACE fragments and original PCR products spanned a 3.2 kb cDNA that contained a 2535-bp open reading frame (ORF), 30 bp of 5Ј-UTR, and 592 bp of 3Ј-UTR (Fig. 1) . No polyA ϩ tail was detected. The ORF encoded an 845-amino acid protein with a predicted size of 95.5 kDa.
An alignment of the beluga AHR amino acid sequence with that of the mouse AHR b-1 allele (Burbach et al., 1992) and the human AHR (Dolwick et al., 1993a ) is shown in Figure 2 .
Among published mammalian AHR sequences, the beluga AHR shares the highest overall amino acid sequence identity (85%) with the human AHR. The beluga and mouse AHRs share 75% identity. The AHR has functional regions whose boundaries have been determined for the mouse AHR (Burbach et al., 1992; Dolwick et al., 1993b; Fukunaga et al., 1995; Poland et al., 1994; Whitelaw et al., 1993) . In brief, the bHLH motif is involved in DNA binding, the PAS domain is involved in ligand binding, dimerization with Arnt, and hsp90 binding, and the C-terminal half of the protein contains sequences that mediate transcriptional activation. When the homologous regions of the beluga AHR were compared to mouse and human AHR genes, the beluga AHR again shared the greatest sequence identity and similarity with the human AHR (Fig. 3) . As in other bHLH/PAS proteins, the N-terminus is much more highly conserved among species as compared to the C-terminus. Clusters of glutamine residues appear among amino acids 598 -675 of the beluga AHR, 20 in total (27%; Fig. 2 ). In the   FIG. 2 . Beluga, human, and mouse AHRs were aligned using the ClustalW alignment program within MacVector software, version 6.5.3 (Oxford Molecular). Human AHR (accession number L19872) and mouse AHR (accession number M94623) sequences were obtained from GenBank. The mouse AHR sequence reflects a Thr at residue 74 instead of a Ser, as noted by Sun et al., (1997) . The functional domains labeled were identified by homology to other mammalian AHRs (see text). The ligand-binding domain (Fukunaga et al., 1995) is in brackets. Identical and similar amino acids are boxed, with identical amino acids shaded darkly, and similar amino acids shaded lightly. Gaps are indicated by dashes. same region, mouse AHR is 28% glutamine, and human AHR is 29% glutamine. This "Q-rich" domain, which has been shown to contribute to transcriptional activation in other transcription factors (Mitchell and Tjian, 1989) , is suggested also to have a role in transcriptional activation by the AHR (Burbach et al., 1992; Jain et al., 1994; Rowlands et al., 1996) .
Certain amino acid changes in the AHR cause dramatic changes in its function. One of these is amino acid 375, of the mouse AHR; an alanine at this position in the Ah b-1 allele confers a 4-to 5-fold greater binding affinity when compared to the Ah d allele, in which this residue is a valine (Ema et al., 1994b; Poland et al., 1994) . Like the high-affinity mouse allele, the beluga AHR has an alanine at the homologous residue 380. Another notable mutation is found in the AHR of mouse Hepa-1 cells (mutant clone c35-3) at residue 216, between the PAS-A and PAS-B domains. A point mutation (C 3 Y) at this site caused a complete loss of DNA binding by the AHR-Arnt heterodimer (Sun et al., 1997) . As with the human AHR and the wild-type mouse Ah b-1 allele, the beluga AHR has the conserved cysteine at homologous residue 221 (222 in human AHR).
Characterization of beluga AHR synthesized in vitro. We analyzed the beluga AHR protein expressed in a rabbit reticulocyte lysate system under control of the SP6 and T7 promoters, with and without modification to create Kozak sequences near the start codon. An autoradiogram of a polyacrylamide gel containing the proteins made with [
35 S]methionine revealed that the construct containing the native AHR sequence, under control of the SP6 promoter (pSP64belAHR), was the most efficiently expressed (not shown). The apparent molecular weight of the in vitro-expressed protein was ϳ110 kDa, consistent with its apparent size as observed by photo-affinity labeling of beluga hepatic cytosol . All functional assays of in vitro (TNT)-expressed protein were henceforth conducted using the pSP64belAHR plasmid.
The relative sizes of the expressed beluga, human, and mouse proteins synthesized in the presence of [
35 S]methionine are consistent with their relative predicted molecular weights of 95.5, 90.6, and 96.0 kDa for pSP64belAHR, pSPORTmoAHR, and pSPORThuAHR products, respectively (Fig.  4A) . Analysis by Western blot (Fig. 4B) confirmed the identity of the expressed proteins as AHRs, and showed that in each case the size of the expressed protein is the same as that derived from tissue cytosol. The relative intensities of the bands do not necessarily reflect quantitative differences between the beluga and mouse AHR expression in liver, because (1) the antibody we used was polyclonal and raised against the N-terminus of the mouse AHR, so equal cross-reactivity cannot be assumed, and (2) (Fig. 5) . The expressed beluga and human AHRs sedimented with peaks at 10.5 S, and the mouse AHR peak was at 10 S. In this experiment, the mouse AHR displayed the highest concentration of specific binding sites (111 fmol AHR/50 l TNT reaction), followed by beluga (69 fmol/reaction) and human (24 fmol/reaction) AHRs. No specific binding was observed with the unprogrammed lysate (Fig. 5F ), confirming that all detectable specific binding was from the expression products alone, and not from lysate proteins. Differences in the total number of specific binding sites among species in this experiment likely reflect variations in the efficiency of in vitro expression as well as species-specific differences in ligand binding properties.
To compare the ligand-binding properties of cloned (in vitro   FIG. 4 . Confirmation of in vitro expression of a beluga AHR. TNT reactions that were conducted in the presence of [
35 S]-labeled methionine and 100 g cytosolic protein isolated from beluga and mouse liver were analyzed by SDS-PAGE. (A) The gel was fixed, treated with Amplify fluorography reagent (Amersham), dried, and exposed to film overnight. (B) An identical set of samples was transferred to 0.2 m PVDF membrane and blotted with antimouse AHR polyclonal Ab (SA-210; BioMol). Immunogenic proteins were visualized with chemiluminescence by exposure to film for 15 min (all lanes) or 30 min (inset lanes 1 and 2).
FIG. 3.
Conservation within functional domains between beluga, mouse, and human AHRs. Pairwise alignments of the functional domains were generated using MacVector version 6.3. The numbers represent percent amino acid identity within the region spanned by the box. expressed) and native (in vivo expressed) AHRs, we also performed velocity sedimentation analyses using cytosols prepared from beluga and C57BL/6 mouse livers, and both exhibited specific binding of [ 3 H]TCDD with peaks sedimenting at 9.5S, similar to the sedimentation coefficients of the in vitro-expressed AHRs. Specific binding in mouse liver cytosol was 24-fmol AHR/mg cytosol protein, and that in beluga liver cytosol was 7.2 fmol/mg. As with the Western-blotting results, the differences in specific binding of mouse and beluga cytosols do not necessarily reflect quantitative differences in AHR expression between these 2 species. When the beluga liver cytosol was treated with as little as 0.025-2.0 mg DCC/mg protein to adsorb free [ 3 H]TCDD, a significant amount of specific binding was lost (not shown). Sensitivity of cytosolic AHR to charcoal treatment has also been observed in human tissues (Manchester et al., 1987; Nakai and Bunce, 1995) , in monkey and dog tissues (Sandoz et al., 1999) , and in fish cells (Lorenzen and Okey, 1990 Poland et al. (1976) . Critical to these experiments is the achievement of an abundance of "free" ligand relative to bound ligand, so that the [ 3 H]TCDD concentrations used to measure the dissociation constant are only minimally reduced by associations with lower-affinity binding sites. A satisfactory balance of detectable specific binding (Ն 500 dpm) and fraction of "free" [
3 H]TCDD (Ն 80%) for the beluga AHR was achieved with an 8-to 10-fold dilution of the lysate (Jensen, 2000) . (Fig. 6) , consistent with the theoretical properties of nonspecific binding sites (low affinity, high capacity, and not saturable). Specific binding was calculated by subtracting nonspecific binding from total binding as described in Materials and Methods, and these values were fit to the Langmuir binding isotherm to determine the equilibrium dissociation constant (K d ) and the theoretical maximum binding (B max ). A representative set of experiments is shown in Figure 6 , and data from 4 independent experiments are summarized in Table 2 . The beluga AHR exhibited high affinity for [ 3 H]TCDD, with a K d that was not significantly different from that of the mouse AHR; both the beluga and mouse AHRs had K d values that were significantly lower than that of the human AHR, indicating greater binding affinities.
DRE binding and transactivation function of the beluga AHR. In order to characterize further the in vitro-expressed beluga AHR, we examined its ability to bind DRE sequences and activate transcription. Figure 7 shows the ability of the beluga and mouse AHRs to bind DNA in an electrophoretic mobility-shift assay (EMSA) using a double-stranded oligonucleotide that contains DRE3 from the mouse Cyp1a1 promoter (Yao and Denison, 1992) . The in vitro synthesized beluga AHR exhibited DNA binding, as demonstrated by the presence of a shifted band that coincided with a similar band produced by the mouse AHR (compare lanes 3 and 10). As expected, there was an absolute requirement for Arnt for DNA binding of both beluga and mouse AHRs (lanes 2-3 and 10 -11). The ability of a wild-type but not a mutant DRE (containing a single base pair change within the consensus DRE sequence) to abolish binding demonstrates the specificity of the DNA binding by the beluga AHR-human Arnt and mouse AHR-human Arnt complexes (lanes 5-6 and 12-13). The ability of the anti-AHR antibody, but not nonspecific IgG, to eliminate the shifted band (lanes 7-8 and 14 -15) demonstrates the presence of the beluga and mouse AHRs in the shifted complex. For both beluga and mouse AHRs, some DRE binding was observed in the absence of added ligand; TCDD caused a slight but reproducible increase in complex formation. Seemingly constitutive DRE binding by AHR-Arnt complexes in gel shift assays is often seen with in vitro-expressed AHRs, as noted previously (Dolwick et al., 1993a; Hirose et al., 1996; Karchner et al., 1999; Numayama-Tsuruta et al., 1997; Powell et al., 1999) . The causes of this apparent AHR activation are not clear, but could include the presence of natural ligands in the reticulocyte lysate (Phelan et al., 1998; Sinal and Bend, 1997) or a deficiency of factors required to stabilize the AHR in the inactive configuration (Bell and Poland, 2000; Kazlauskas et al., 2000; LaPres et al., 2000; Petrulis et al., 2000) . Figure 8 shows the ability of the beluga AHR to activate transcription of a luciferase reporter gene under control of murine Cyp1a1 enhancer sequences in a transient cotransfection assay. Luciferase transcription was low to undetectable when the cells were transfected with pGudLuc6.1 alone or together with a human Arnt expression plasmid (lanes 1-4) . Cotransfection of increasing concentrations of pcDNAbelAHR (0.5, 1.0, 5.0, 10, or 50 ng) resulted in a DNA concentrationdependent increase in transcription of the luciferase reporter (lanes 5-8 for 10 and 50 ng; lower DNA concentrations not shown). This occurred in the absence of cotransfected human Arnt expression plasmid, most likely because of the low levels of endogenous Arnt in these cells (lanes 9 -10); however, luciferase transcription was enhanced in the presence of exogenous Arnt (compare lanes 7-8 to 9 -10). The mouse AHR expression vector pSPORTmoAHR also stimulated transcription of the luciferase reporter (lanes 11-16) . The greater degree of transactivation with the beluga AHR as compared to the mouse AHR could be because of the use of the pcDNA vector for beluga AHR expression; this vector contains the SV40 origin of replication, which leads to high plasmid copy number in COS-7 cells. In cells expressing beluga or mouse AHRs, luciferase activities in the absence of added TCDD were equal or nearly equal to those when TCDD (10 nM) was added. This "constitutive" (exogenous ligand-independent) reporter-gene expression and the resulting low TCDD inducibility in transient transfection assays have been noted by others. They are likely due to overexpression of the AHRs in the transfected cells (Fukunaga et al., 1995; Fukunaga and Hankinson, 1996; Mason et al., 1994; Matsushita et al., 1993; Whitelaw et al., 1994; ) , possibly coupled with a deficiency of proteins required for cytoplasmic retention of unliganded receptor (Kazlauskas et al., 2000; LaPres et al., 2000; Petrulis et al., 2000) . Nevertheless, the results of these experiments clearly demonstrate the ability of the beluga AHR to bind to DRE sequences and subsequently to activate transcription.
DISCUSSION
The overall objective of these studies was to begin to assess the potential impact of a persistent and toxic class of environmental contaminants, the PHAHs, on the health of cetaceans. The toxicity of PHAHs has been clearly established in other mammalian species. For this reason, PHAHs, among other contaminants and factors related to environmental degradation, have been implicated in apparent increases in marine mammal disease and mortality. However, species-specific variability in sensitivity to PHAHs (Pohjanvirta and Tuomisto, 1994; Poland and Knutson, 1982) confounds and limits broad speculation on the toxicological significance of the high tissue burdens that are observed in marine mammals.
One approach for assessing the potential toxicological significance of PHAHs in a given species is to examine proteins involved in the mechanism of toxicity. We chose to examine Note. K d s of AHRs were analyzed using 1-way ANOVA (p ϭ 0.0052, F ϭ 9.9) and compared using the Tukey's multiple comparison test. For all 4 experiments, the range of r 2 values for fit of specific binding data to the Langmuir isotherm was 0.95-0.99 (beluga), 0.96 -0.98 (mouse), 0.81-0.98 (human), and 0.95-1.0 (upl).
FIG. 6.
Saturation binding curves for beluga, mouse, and human AHR. The panels show representative binding curves for the in vitro-expressed products derived from pSP64 belAHR, pSPORTmoAHR, and pSPORThuAHR. Nine concentrations of [ 3 H]TCDD were incubated with TNT reaction diluted in AHR buffer, as described in Materials and Methods. Open squares, total binding; open circles, nonspecific binding as determined using an empty pSP64 vector ("unprogrammed lysate"). Filled triangles, specific binding determined by subtracting the calculated nonspecific binding values from the total binding in each tube (100 dpm ϭ 65 pM [ 3 H]TCDD). The curve through the specific binding points was derived by a nonlinear curve fit to the Langmuir binding isotherm using SigmaPlot software (Jandel Scientific). R 2 values (goodness of fit) for this experiment were 0.95 (beluga), 0.96 (mouse), 0.81 (human), and 0.97 (upl). the AHR, a protein known to interact directly with PHAHs and to play an essential role in PHAH toxicity (Fernandez-Salguero et al., 1996; Mimura et al., 1997; Peters et al., 1999) . However, biochemical examination requires intact proteins from high quality tissue samples, which are difficult to collect from marine mammals because of the paucity of sampling opportunities, delays in excising tissues (leading to autolysis), and the in vitro lability and low abundance of the AHR. To circumvent these and other problems associated with the sampling and analysis of marine mammal tissues, we cloned a beluga AHR, expressed it in vitro, and characterized the TCDD-binding affinity and other functional properties of the expressed protein in comparison with AHRs from mouse and human. The results of our analyses provide suggestive evidence that beluga, and possibly other cetaceans, may be sensitive to AHR agonists, thus implying that PHAHs have the potential to affect cetacean health.
Beluga AHR Shares High Sequence Identity with Other Mammalian AHRs
Cloning and sequence analysis of a full-length cetacean AHR confirms and extends earlier observations of proteins in cytosols from beluga liver and a dolphin cell line that bind dioxin specifically (Carvan et al., 1994; Hahn et al., 1994) . The beluga AHR possesses major functional domains that are characteristic of AHRs, including the bHLH, PAS A, PAS B, and glutamine-rich regions. As with other AHRs, the N-terminus of the beluga AHR is highly conserved, while the C-terminus is much less so, and might be termed "hypervariable," as noted by others (Dolwick et al., 1993a) . Phylogenetic analyses (not shown) demonstrate that the beluga AHR amino acid sequence groups with the "AHR1 clade" rather than the "AHR2 clade" recently identified in some vertebrates (Hahn et al., 1997; Karchner et al., 1999) . Overall, the beluga AHR sequence is most closely related to the human AHR; these 2 proteins differ by only 3 residues in length and share 85% amino acid identity. The beluga AHR shares 75% identity with the mouse Ah b-1 allele (Burbach et al., 1992) , although within the bHLH and PAS domains this identity is much higher. The closer relationship of the beluga AHR to the human AHR, as compared to the mouse AHR, is unexpected in light of the phylogenetic relationships between cetacea, rodentia, and primates determined from other gene sequences (Madsen et al., 2001; Murphy et al., 2001) . The basis and significance of this observation are not yet clear.
Despite the high degree of sequence identity among mammalian AHRs, subtle changes in the amino-acid sequence can cause remarkable changes in AHR function (Pohjanvirta et al., 1998; Poland et al., 1994; Sun et al., 1997) that could be the basis for species-specific differences in sensitivity to AHR ligands. A much greater understanding of the AHR structurefunction relationship is required before function may be deduced accurately from AHR sequence data. For this reason, we characterized the in vitro binding affinity and other properties of the beluga AHR.
Beluga Whales Possess a High Affinity AHR
In order to conduct a comparison of the beluga AHR with AHRs from terrestrial mammals that have been reasonably well characterized, we chose a relatively "high affinity" and a 
FIG. 8.
Transcriptional activation by the beluga AHR. COS-7 cells were transfected with beluga and mouse AHR expression plasmids plus human Arnt where indicated. Each experimental and control well included 20ng luciferase reporter plasmid (pGudLuc6.1), and 3 ng renilla luciferase control plasmid (pRL-TK). Each combination of DNA was brought to ϳ300 ng total DNA with empty pcDNA3.1 vector. Five h after transfection, cells were dosed with DMSO or TCDD in DMSO, and cells were lysed and assayed 18 h later. Results shown represent means Ϯ SD of 3 wells per group in one experiment. Transfection experiments using the beluga AHR were performed 3 times, with similar results.
relatively "low affinity" AHR to use alongside the beluga AHR in our experimental system to determine comparative TCDDbinding affinities. The high affinity AHR was the mouse Ah b-1 allele (Burbach et al., 1992) . The representative low affinity AHR that we used was the human AHR that was cloned from the HepG2 hepatoma cell line (Dolwick et al., 1993a) . In vitro, the HepG2 AHR, like the mouse Ah d allele, has a 4 -5-fold lower affinity for TCDD than does the mouse Ah b-1 allele (Ema et al., 1994b; Poland et al., 1994) .
Determination of the K d for in vitro-expressed beluga, mouse, and human AHRs by saturation binding showed that the beluga AHR is a high affinity AHR. Absolute binding affinities are highly dependent on the protein concentrations used in the incubations, with apparent binding affinities decreasing with increasing protein concentrations (Bradfield et al., 1988) . Therefore, K d values are best compared among those determined under similar experimental conditions and protein concentrations. Table 3 shows several intralaboratory data sets for which K d s for mouse (Ah b-1 or Ah d allele) and human AHRs were reported. When mouse and human AHR K d values are compared within laboratories, the affinity of the mouse AHR (product of the Ah b-1 allele) is greater than that of the human AHR in each case. Regardless of whether the samples were tissue cytosols, cell-line cytosols, or in vitroexpressed proteins, the human AHR K d values were 3-to 8-fold greater than those of the mouse. The robustness of this difference in binding affinities between experimental conditions and laboratories indicates a real functional difference between the mouse and human AHRs. Our findings show a 2.4-fold difference in binding affinity between mouse and human AHRs and a nearly 4-fold difference between beluga and human AHRs (p Ͻ 0.05, Table 2 ). Thus, the beluga AHR allele described here encodes a high affinity AHR.
These relative binding affinities may be used to infer the potential susceptibility of beluga to PHAH. The beluga AHR has a binding affinity that is similar to that of the mouse (Ah b-1 ) AHR, but ϳ4-fold greater than the binding affinity of the human AHR (Table 2 ). In the case of inbred mice, a single alanine to valine change at residue number 375 is responsible for a 4 -5 fold difference in the in vitro ligand binding affinities observed between the Ah b-1 allele and the Ah d alleles (Ema et al., 1994b; Poland et al., 1994) . At the homologous residues in the beluga and human AHRs, the beluga AHR possesses an alanine (Ala 380 ), as in the Ah b-1 allele, while the human AHR has a valine (Val 381 ), as in the Ah d allele. This difference may contribute to the 4-fold difference in binding affinity between the beluga and human AHRs observed here. In in vivo studies using congenic mice, the homozygous Ah b-1 mouse strain shows 8-to 24-fold higher sensitivity to toxic effects compared to the homozygous Ah d strain (Birnbaum et al., 1990) . Similarly, in a comparison among several bird species, the relative sensitivities to TCDD induction of CYP1A reflect the relative TCDD-binding affinities of their AHRs (Sanderson and Bellward, 1995) . Thus, in the case of mouse strains and bird species, the relative AHR binding affinity can predict PHAH sensitivity. Of course, the AHR is not the only factor that can influence the susceptibility to PHAH effects. Altered expression or function of other components of the AHRdependent signal transduction pathway, as well as other species-specific characteristics (e.g., biotransformation activities, pharmacokinetic differences) can also influence responsiveness (reviewed in Hahn, 1998b) . Nevertheless, it is clear that the AHR plays an important-and possibly primary-role in determining susceptibility to PHAH toxicity. The presence of a high affinity AHR in beluga suggests that this species may be particularly sensitive to PHAH. Evidence for induction of CYP1A1 in beluga exposed to relatively low concentrations of PCBs in the Arctic (White et al., 1994) is consistent with this hypothesis. 
The Beluga AHR Binds DREs and Is Transcriptionally Active
To more completely assess the function of the beluga AHR, we examined its ability to participate in sequence-specific protein-DNA interactions with a murine DRE and to activate transcription of a reporter gene under control of a murine enhancer element containing multiple DRE sequences. These properties are characteristic of rodent and human AHRs (Burbach et al., 1992; Dolwick et al., 1993a,b; Fukunaga et al., 1995; Whitelaw et al., 1994) but had not yet been examined in a cetacean or other marine mammal. The results of these assays clearly demonstrated that the beluga AHR is capable of high affinity, sequence-specific, and Arnt-dependent interactions with mammalian DREs, and that this receptor is able to activate transcription of target genes, presumably through the glutamine-rich region or other putative transactivation domains in the C-terminal half of this protein. The demonstrated functionality of the beluga AHR in vitro is consistent with evidence for inducible CYP1A1 expression in vivo (White et al., 1994; .
Significance of a High Affinity AHR in Cetaceans
Establishing a cause and effect relationship between contaminant burdens and disease in marine mammals is difficult. Because controlled dosing experiments in cetaceans are usually not feasible, a "weight of evidence" approach has been proposed for investigating the existence of contaminant-induced toxic effects in marine mammals (Ross, 2000) . Currently, 4 lines of research are seen as contributing to this approach. These include (1) epidemiological and descriptive studies of wild populations, (2) mechanistic studies in laboratory rodents, (3) feeding studies in captive animals (possible only in limited cases), and (4) feeding studies involving rodents exposed to marine mammal diets or contaminated tissues.
Our results suggest a fifth type of data that can contribute to the weight-of-evidence approach: species-specific cloning and characterization of proteins involved in mechanisms of toxicity. This approach has been used recently to characterize the AHR and other receptors in nonmammalian species (Abnet et al., 1999; Karchner et al., 1999 Karchner et al., , 2000 Matthews and Zacharewski, 2000) , but has not previously been applied to marine mammals. Such data can provide a link between mechanistic studies in laboratory rodents and epidemiological findings in wildlife. In this context, our study has demonstrated that belugas possess an AHR that shares a high degree of sequence identity with other mammalian AHRs, shares key functional properties with these AHRs, and binds TCDD with an affinity that is at least as high as a high affinity AHR from a dioxinsensitive strain of mouse.
It may be informative to compare the binding affinity of the in vitro-expressed beluga AHR with the concentration of AHR ligands in beluga tissues, keeping in mind that such comparisons are complicated by the many differences that exist between in vitro and in vivo systems. The concentrations of "TCDD equivalents" (TEQs) in livers of St. Lawrence belugas are in the range of 0.01 to 0.13 nM (Gauthier et al., 1998; Metcalfe et al., 1999) ; Muir et al., 1996) . 3 Using the K d of 0.43 nM for the in vitro-expressed beluga AHR (Table 2) and extrapolating directly to whole liver, these TEQ concentrations would be predicted to result in 2% to 23% receptor occupancy. At such levels of AHR occupancy, some effects might be expected, especially if belugas possess "spare" AHR capacity as shown in other systems (Hestermann et al., 2000) .
The presence of a high affinity AHR in a cetacean is consistent with a role for the AHR and PHAHs in the toxic effects observed in environmentally exposed cetaceans. Additional factors that will influence the sensitivity of cetaceans to PHAHs include the PHAH-AHR structure-binding relationships and the tissue-and cell-specific pattern of AHR expression. These questions are currently being addressed using the cloned beluga AHR cDNA and probes derived therefrom (Jensen, 2000) . Together, these results demonstrate that the use of in vitro-expressed proteins is a promising approach for addressing molecular and biochemical questions concerning PHAH toxicity in endangered or protected species, in which logistical and ethical concerns preclude testing in live animals.
